Optimal Remifentanil Ce for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 364 participants.

Also called NCT03132519

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 364 participants (enrolled count) (from the registry)
Sponsor
Fundacion Clinica Valle del Lili (from the registry)
Registry
  • NCT NCT03132519
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Colombia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03132519. Randomized; quadruple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2015-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal Remifentanil Ce for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation
Acronym
REX
Condition
Cough
Condition
Hypertension
Intervention (Drug)
Remifentanil
Lead sponsor
Fundacion Clinica Valle del Lili (class: other)

Record details

Record id
cardio:ct-nct03132519
Content hash
b010d7ad3eb3c15e9de2ec3fd484874810db216871a1d5693863e8a8de354a20